We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent Registers Cedar Creek Facility with FDA to Manufacture Diagnostic Products
News

Agilent Registers Cedar Creek Facility with FDA to Manufacture Diagnostic Products

Agilent Registers Cedar Creek Facility with FDA to Manufacture Diagnostic Products
News

Agilent Registers Cedar Creek Facility with FDA to Manufacture Diagnostic Products

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Registers Cedar Creek Facility with FDA to Manufacture Diagnostic Products"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies Inc. has announced that its Cedar Creek, Texas, reagent manufacturing facility has been registered with the U.S. Food and Drug Administration as a medical device establishment.

This registration is required for the manufacture of diagnostic products, which Agilent intends to develop.

“Many of Agilent’s proven research platforms hold potential in diagnostic markets,” said Robert Schueren, Agilent vice president, Genomics.

Schueren continued, “We’ve made a commitment to bring improved diagnostic tools to the medical community. Having an FDA-registered manufacturing facility is yet another step in this endeavor.”
Agilent currently manufactures and packages a wide range of research bioreagents at the 80,000-square-foot Cedar Creek facility, including enzyme-based reagents and high-fidelity oligonucleotides.

The company has built separate, dedicated diagnostics space with additional room for expansion as needed.

Advertisement